Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard F Little

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
Leukemia|July 18, 2021
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202Amy S Ruppert, Allison M Booth, Wei Ding, et al.
Blood|September 10, 2013
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patientsStefan K Barta, Xiaonan Xue, Dan Wang, et al.
The Journal of Molecular Diagnostics : JMD|May 17, 2025
Analytical Performance of the NCI-myeloMATCH Assay: A Rapid Turnaround Genomic Profiling Assay for Myeloid DisordersCecilia Cs Yeung, Srikrishna K Narava, Ting-Chia Chang, et al.
The New England Journal of Medicine|August 1, 2019
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic LeukemiaTait D Shanafelt, Xin V Wang, Neil E Kay, et al.
The Lancet. Haematology|December 4, 2018
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 studyKieron Dunleavy, Michelle A Fanale, Jeremy S Abramson, et al.
Annals of Hematology|November 30, 2023
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsJan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, et al.
Blood|April 2, 2011
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United StatesJeffrey I Cohen, Elaine S Jaffe, Janet K Dale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826Sharon M Castellino, Hongli Li, Alex F Herrera, et al.
Blood|April 15, 2022
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trialTait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 8, 2019
Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 TrialRichard F Ambinder, Juan Wu, Brent Logan, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Leukemia|July 18, 2021
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202Amy S Ruppert, Allison M Booth, Wei Ding, et al.
Blood|September 10, 2013
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patientsStefan K Barta, Xiaonan Xue, Dan Wang, et al.
The Journal of Molecular Diagnostics : JMD|May 17, 2025
Analytical Performance of the NCI-myeloMATCH Assay: A Rapid Turnaround Genomic Profiling Assay for Myeloid DisordersCecilia Cs Yeung, Srikrishna K Narava, Ting-Chia Chang, et al.
The New England Journal of Medicine|August 1, 2019
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic LeukemiaTait D Shanafelt, Xin V Wang, Neil E Kay, et al.
The Lancet. Haematology|December 4, 2018
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 studyKieron Dunleavy, Michelle A Fanale, Jeremy S Abramson, et al.
Annals of Hematology|November 30, 2023
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsJan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, et al.
Blood|April 2, 2011
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United StatesJeffrey I Cohen, Elaine S Jaffe, Janet K Dale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826Sharon M Castellino, Hongli Li, Alex F Herrera, et al.
Blood|April 15, 2022
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trialTait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 8, 2019
Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 TrialRichard F Ambinder, Juan Wu, Brent Logan, et al.
Pageof 11